PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its needle-free injection technology, will present insights from several DNA cancer vaccine partner trials using PharmaJet’s Precision Delivery Systems™ at the World Vaccine Congress 2025 on April 23, 2025 at 12:25 PM ET.
Titled What if Delivery Is the Missing Link in Cancer Immunotherapy? Insights from DNA Cancer Vaccine Trials Using Needle-Free Injection Delivery, the presentation will share data showing that PharmaJet technology can induce robust T cell responses and tumor/lesion reduction in difficult-to-treat cancer populations. Several partner vaccine trials will be discussed including specific DNA cancer vaccines administered with the PharmaJet systems.
“We are proud to support our oncology partners in their development of cancer vaccines and therapeutics with our needle-free delivery systems,” said Nathalie Landry, Chief Scientific Officer, PharmaJet. “Our body of data highlights how our needle-free technology can be expected to enhance vaccine immune response, and how it contributes to inducing T cell-mediated immune responses in difficult-to-treat cancer populations. We are encouraged by these results and the potential for needle-free delivery to further enhance various lines of cancer vaccines and therapies.”
PharmaJet will also be delivering a pre-conference presentation entitled Navigating the Immune System starts with Precise Delivery, during the Vaccine Delivery Session on April 21, 2025, from 2:00 – 5:00 PM in Room 202A.